Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Give written informed consent to participate.~2. Age 18 - 49 years old.~3. Judged suitable by the PI, as determined by medical history, physical examination, vital signs, and clinical safety laboratory examinations.~4. Willing to use oral, implantable, transdermal or injectable contraceptives, or sexual abstinence, from screening and until 28 days after second vaccine dose.~5. Willing to adhere to the requirements of the study and willing and able to communicate with the Investigator and understand the requirements of the study.~Exclusion Criteria:~1. Abnormal screening hematology or chemistry value per the FDA Toxicity Guidance.~2. Pulse rate or blood pressure outside the reference range for this study population and considered as clinically significant by the Investigator.~3. Has an acute or chronic medical condition or history of a medical condition that, in the opinion of the Investigator, would render the study procedures unsafe or would interfere with the evaluation of the responses.~4. Presence or clinically significant history of lung disease, asthma, chronic obstructive pulmonary disease (COPD), or otherwise poor lung function.~5. Any confirmed or suspected immunosuppressive or immunodeficient state.~6. Presence of household member or close personal or professional (i.e., healthcare worker) who is a child under one year of age; is pregnant; has known immunodeficiency or is receiving immunosuppressant medication; is undergoing or soon to undergo cancer chemotherapy; has been diagnosed with emphysema, COPD, or other severe lung disease and resides in a nursing home; and/or has received a bone marrow or solid organ transplant.~7. Females who are pregnant or lactating.~8. Acute febrile illness within 72 hours prior to vaccination.~9. Any condition, in the opinion of the Investigator, (such as subjects who have medically high-risk conditions) that might interfere with the primary study objectives for safety of the study subject.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- Low dose Sing2016 M2SR (Type: EXPERIMENTAL): Low dose Sing2016 M2SR will be administered intranasally on days 1 and 29
- Medium dose Sing2016 M2SR (Type: EXPERIMENTAL): Medium dose Sing2016 M2SR will be administered intranasally on days 1 and 29
- High dose Sing2016 M2SR (Type: EXPERIMENTAL): High dose Sing2016 M2SR will be administered intranasally on days 1 and 29
- Low dose Bris10 M2SR (Type: ACTIVE_COMPARATOR): Low dose Bris10 M2SR will be administered intranasally on days 1 and 29
- Placebo (Type: PLACEBO_COMPARATOR): Saline will be administered intranasally on days 1 and 29

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete